73 results about "Human pathogen" patented technology

Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens. A novel strain of Bacillus subtilis was isolated from the gastrointestinal tract of poultry and was found to produce a factor or factors that have excellent inhibitory effects on Clostridium perfringens, Clostridium difficile, Campylobacter jejuni, Campylobacter coli, and Streptococcus pneumoniae. The factor(s) retain full viability and antimicrobial activity after heat treatment. The invention provides a method of treatment of pathogenic microorganisms including C. perfringens.

A method for using FIFRA-exempt substances (e.g., essential oils), materials having one or more such substances coated thereon and/or incorporated therein, and products that are made using these materials, are provided. The properties demonstrated by the inventive materials and products include the control or killing of, for example, decay causing organisms, human pathogens, insects, nematodes, bivalves and spats, and odor removal by destruction of bacteria, mold, fungus and yeasts.

Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function; in modeling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy.

Chimeric parainfluenza viruses (PIVs) incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric Ply genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.

A method to control, inhibit, and kill pathogens and normal microbial strains that includes, but not limited to plant, animal and human pathogens, biofilm forming microbes, biofouling microbes, algae, fungi, bacteria, virus and protozoa using natural SL, MSL derivative and combinations thereof encompassed by the combination invention.

Provided are methods for growing and shipping sprouts and microgreens in the same container, growing while in shipment using moisture provided in a water-absorbent layer, with optional added beneficials, and including methods for producing sprouts and microgreens for consumption, and for pharmaceutical/nutriceutical use, comprising growth of sprouts in retail-ready containers, the container comprising a moisture-retaining layer of agar media or the like providing water for growth and obviating the need for irrigation during sprout growth. In certain aspects, media is supplemented with beneficial organisms or additives such as probiotic microbes, vitamins (e.g., B12), cofactors, nutrients, and other items (e.g., phytochemicals, natural colors, and antioxidants) which promote the growth of the beneficial microbes on the product, and/or which become incorporated into the product. In certain aspects, added beneficial microorganisms are selected to compete antagonize human pathogens such as Listeria, Salmonella, enterohaemorrhagic E. coli, Yersinia, and/or spoilage organisms (e.g., Erwinia, Pseudomonas and Xanthomonas).

The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (CBD) and a second portion, which comprises an enzymatic active domain (EAD) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors. The chimeric polypeptides of the present invention are useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, chimeric polypeptides of the present invention have been shown to effectively kill various bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), as well as other human pathogens. Thus, provided are compositions comprising chimeric polypeptides according to the present invention, variants or fragments thereof, and the use of such compositions in prophylaxis or therapy of bacterial diseases, bacterial infections or bacterial colonisations.

A fluid suspended particle classifier system detects particles of one or more classes from a predetermined recognized set of classes based on multiple images of groups of particles. An artificial intelligence classifier combines subtle clues in the images including particle morphology, size, spectral response, fluorescence, movement, density, or aggregation. Class-specific concentration estimations have a low limit of detection, and a high dynamic range. There is a tolerance for mixtures of classes of particles having widely differing sizes and concentrations. Selected particle images, histories and analysis are communicated and stored. Consumable use and manual procedures are minimized or avoided, allowing remote, unattended, real-time operation. In remote water quality monitoring, the appearance of particles resembling the Escherichia coli bacterium, an occasional human pathogen, causes an alarm.

Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.

The invention relates to the field of microbial disease control and in particular relates to a probiotic with bacteriostatic ability. The probiotic is Enterobacter ludwigii-PC88, is collected in China General Microbiological Culture Collection Center (CGMCC) on June 24, 2013, and has a collection number of CGMCC No.7814. The probiotic is separated from intestinal tracts of healthy flounders. The pure culture of the probiotic has relatively strong inhibitory effects on aquatic pathogens such as vibrio splendidus, vibrio harveyi, vibrio parahaemolyticus, pseudomonas aeruginosa and vibrio anguillarum, also can inhibit growth of known human pathogens such as tritirachium album, staphylococcus aureus and klebsiella pneumoniae, and has resistance to ampicillin. The pure culture or composition of the probiotic can be used for control of aquaculture diseases and development of novel antibacterial materials, and has good application prospects.

The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR−/−, STAT1−/− or both PKR−/− and STAT1−/−. The virus is selected from the group consisting of Rhabdovirus and picomavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.

Preservative compositions using toxicologically acceptable ingredients, and employing a pH of 9.0 or above for at least part of the process, for reducing the initial population and controlling the growth of spoilage bacteria and human pathogens and for preventing unwanted color changes in fresh and processed produce, particularly mushrooms. Aqueous solutions of preservatives are prepared and applied in multiple stages to the mushrooms, by spraying or immersion. More specifically, disclosed is a method for preserving fresh and processed mushrooms, comprising the steps of: contacting the mushrooms with an antimicrobial solution having a pH of about 9.0 or above; and rinsing the mushrooms one or more times immediately after the contacting step with pH-neutralizing solutions having a pH sufficient to return the produce to its physiological pH. In a preferred embodiment, electrolyzed basic water is used in the first stage high-pH rinse step and electrolyzed acid water is used in the second stage neutralizing solution step. Tyrosinase inhibitors such as ascorbates, erythorbates, EDTA or calcium chloride are added to the neutralizing solutions to inhibit enzymatic browning.

The invention provides a gRNA for targeting a pathogen gene RNA, and the invention also provides a human pathogen gene detection method and detection kit based on a clustered regularly interspaced short palindromic repeat (CRISPR)-C2c2 system. The detection method combines the advantages of the gRNA in targeting to recognize a pathogen gene transcript RNA (target RNA sequence) and the characteristic that when the CRISPR-C2c2 complex detects the target RNA sequence, the complex cleaves a reporting RNA with a detection marker to release detectable signals, the CRISPR-C2c2 system is applied to pathogen gene detection, and has high sensitivity and high accuracy. The detection method and the detection kit have great commercial application value.

The present invention relates to a method of reducing the viability of tumor cells comprising administering to the tumor cells a virus that is not a common human pathogen. The virus preferably exhibits a differential susceptibility wherein normal cells are not affected by the virus. The differential susceptibility was more pronounced in the presence of interferon. Tumors were characterized by low or no PKR activity, or PKR-/-, STAT1-/-, or both PKR-/- and STAT1-/-. The virus is selected from baculoviruses and picornaviruses, preferably vesicular stomatitis virus (VSV) or derivatives thereof.

The present invention provides isolated peptides relating to the autoimmune disease pemphigus vulgaris. The peptides relating to pemphigus vulgaris are self epitopes derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharmaceutical preparations for tolerizing and/or immunizing individuals are provided as well as methods relating thereto. Methods are provided for identifying other self and non-self epitopes involved in human autoimmune disease and similar pharmaceutical preparations and methods of use for these epitopes are also provided.

The present invention relates to the discovery of a toxin-antitoxin system in opportunistic human pathogen Pseudomonas aeruginosa and to the applications of this discovery including the stabilization of plasmids useful in the field of recombinant DNA technology for production of genes and their products. The Phd-like (prevent host death) antitoxin protein and ParE-like toxin protein of the invention are shown in FIGS. 1, 2 and 15.

The invention relates to an in vitro method for the detection and/or identification of a human pathogen and/or genetic material thereof comprising subjecting a sample comprising or suspected of comprising a human pathogen and/or genetic material thereof to a multiplex real-time polymerase chain reaction (RT-PCR), wherein said method comprises amplification of PCR products that enable discrimination between bacterial and fungal pathogens, discrimination between gram positive and gram negative bacterial pathogens, and identification of Staphylococcus and/or Candida pathogens if present in said sample. The invention also relates to the oligonucleotides used in said method and a set of oligonucleotides and a kit for carrying out the method.